ReviewBlood neoplasia2025
Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma.
Yoshito Nishimura et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
ReviewBlood neoplasia2025
Yoshito Nishimura et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.